Ra Pharmaceuticals Inc (NASDAQ:RARX) Insider Sells $106,709.50 in Stock

Ra Pharmaceuticals Inc (NASDAQ:RARX) insider Alonso Ricardo sold 2,285 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The shares were sold at an average price of $46.70, for a total value of $106,709.50. Following the completion of the sale, the insider now owns 6,858 shares of the company’s stock, valued at $320,268.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ RARX traded down $0.12 on Thursday, hitting $46.54. 255,421 shares of the company’s stock were exchanged, compared to its average volume of 624,098. The stock has a 50-day moving average of $28.67 and a 200-day moving average of $27.01. The company has a current ratio of 15.30, a quick ratio of 15.30 and a debt-to-equity ratio of 0.02. Ra Pharmaceuticals Inc has a 52 week low of $11.27 and a 52 week high of $47.08. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -22.59 and a beta of 1.34.

Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.03). As a group, analysts predict that Ra Pharmaceuticals Inc will post -1.98 earnings per share for the current year.

Several brokerages recently issued reports on RARX. Zacks Investment Research cut Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Robert W. Baird cut Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $48.00 price target for the company. in a research note on Thursday, October 10th. BMO Capital Markets cut Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price target for the company. in a research note on Thursday, October 10th. Jefferies Financial Group cut Ra Pharmaceuticals from a “buy” rating to a “hold” rating and set a $48.00 target price for the company. in a research note on Thursday, October 10th. Finally, Credit Suisse Group cut Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. Ra Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $44.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of Montreal Can increased its holdings in shares of Ra Pharmaceuticals by 218.0% during the second quarter. Bank of Montreal Can now owns 3,832 shares of the company’s stock worth $115,000 after buying an additional 2,627 shares in the last quarter. Meeder Asset Management Inc. increased its holdings in shares of Ra Pharmaceuticals by 26.2% during the third quarter. Meeder Asset Management Inc. now owns 6,209 shares of the company’s stock worth $147,000 after buying an additional 1,290 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Ra Pharmaceuticals during the first quarter worth $229,000. Virginia Retirement Systems ET AL increased its holdings in shares of Ra Pharmaceuticals by 12.9% during the second quarter. Virginia Retirement Systems ET AL now owns 10,500 shares of the company’s stock worth $316,000 after buying an additional 1,200 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System acquired a new position in shares of Ra Pharmaceuticals during the second quarter worth $373,000. Hedge funds and other institutional investors own 91.59% of the company’s stock.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Further Reading: Is the QQQ ETF safe?

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.